OFM
TRVI icon

Omega Fund Management’s Trevi Therapeutics TRVI Stock Holding History

Omega Fund Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,263,408
Closed -$1.77M – 26
2021
Q3 		$1.77M Hold
1,263,408
– – 0.2% 25
2021
Q2 		$2.84M Hold
1,263,408
– – 0.32% 21
2021
Q1 		$3.42M Hold
1,263,408
– – 0.32% 20
2020
Q4 		$3.33M Sell
1,263,408
-112,499
-8% -$364K 0.5% 16
2020
Q3 		$5.54M Hold
1,375,907
– – 1.5% 11
2020
Q2 		$9.05M Buy
1,375,907
+112,499
+9% +$396K 2.48% 8
2020
Q1 		$4.16M Hold
1,263,408
– – 1.72% 12
2019
Q4 		$4.74M Hold
1,263,408
– – 1.51% 11
2019
Q3 		$5.68M Hold
1,263,408
– – 1.75% 10
2019
Q2 		$9.48M Buy
+1,263,408
New +$10.9M 2.42% 8

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Omega Fund Management's TRVI Position: Q4 2021 in Review

Omega Fund Management sold out of Trevi Therapeutics (TRVI) in Q4 2021, closing a stake of 1,263,408 shares — an estimated $1.77M sold.

Omega Fund Management first reported a position in TRVI in Q2 2019 and held it in 10 quarters. The position peaked at $9.48M in Q2 2019. 17 funds tracked by Wall St. Rank hold TRVI as of Q4 2021.

  • Omega Fund Management reported no remaining Trevi Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Omega Fund Management sold 1,263,408 Trevi Therapeutics shares in Q4 2021, an estimated $1.77M.
  • Omega Fund Management first reported a position in Trevi Therapeutics in Q2 2019 and held it in 10 quarters.
  • Omega Fund Management's Trevi Therapeutics position peaked at $9.48M in Q2 2019.
  • 17 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2021.

Based on Omega Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.